Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Non-Current Assets (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Non-Current Assets for 4 consecutive years, with $13.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 4.05% to $13.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $13.5 million for FY2025, N/A changed from the prior year.
  • Non-Current Assets for Q4 2025 was $13.2 million at Neuphoria Therapeutics, down from $13.4 million in the prior quarter.
  • The five-year high for Non-Current Assets was $16.8 million in Q2 2022, with the low at $13.2 million in Q4 2025.
  • Average Non-Current Assets over 4 years is $14.3 million, with a median of $13.7 million recorded in 2024.
  • The sharpest move saw Non-Current Assets fell 9.04% in 2023, then fell 4.05% in 2025.
  • Over 4 years, Non-Current Assets stood at $16.8 million in 2022, then dropped by 9.04% to $15.3 million in 2023, then dropped by 10.07% to $13.8 million in 2024, then decreased by 4.05% to $13.2 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $13.2 million, $13.4 million, and $13.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.